|
SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
|
Aug 2012
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
|
Jul 2012
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Calculator-free point-of-care prognostication in myelodysplastic syndromes.
|
Jan 2019
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
|
Mar 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH).
|
Oct 2013
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes.
|
Apr 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R
|
Sep 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
